Farmas USA

Lovaza TRx: 7,715 (down 2.2% from 7,892) NRx: 2,331 (down 7.4% from 2,518)

Generic Lovaza:. NRx66,154 (up 2.1% from 64,774)
NRx 25,837 (down 3.2% from 26,687)

Threshold Pharmaceuticals (NASDAQ:THLD) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 1 by 7 Wall Street Analysts. 7 analysts have added the counter in their list of strong buys.

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD): According to 5 Analysts, The short term target price has been estimated at $ 11.9.The target price could deviate by a maximum of $1.6 from the forecast price. In the near term, the target price could hit a high of $14 and a low of $ 10.

THLD

GALE

Toca subir:

today announced the closing of the exercise of the underwriters' option to purchase an additional 3,653,846 shares of common stock of Galena at a price of $1.457 per share as part of the firm commitment underwritten offering that closed initially on March 18, 2015.

The additional net proceeds to Galena from the exercise of the option with respect to the shares are approximately $5.4 million, bringing the total net proceeds to Galena from the offering to approximately $40.8 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Galena.

Raymond James & Associates, Inc. acted as the sole book-running manager for the offering. Roth Capital Partners acted as lead manager, and Maxim Group LLC, Noble Life Science Partners, and MLV & Co. LLC acted as co-managers.

Galena intends to use the net proceeds from the offering to fund its operations, including the ongoing commercialization of Abstral® (fentanyl) Sublingual Tablets and Zuplenz® (ondansetron) Oral Soluble Film, its ongoing Phase 3 PRESENT study and other clinical trials of its product candidates, and for other working capital and general corporate purposes.

Bien, ADXS como os he ido comentando estas semanas, ya está por encima de los 20 dólares... No sé ahora mismo hasta dónde puede llegar... Viento en popa a toda vela... Ha pasado de una capitalización de mercado de unos 60 millones de dólares a unos 600 millones en estos momentos... Ojalá los eufóricos que la sitúan en 60-100 dólares acierten... Sigo sin vender...!!!

Adjunto la buena nueva de hoy. La compañía ha sido incluída en el Loncar Cancer Immunotherapy Index.

http://globenewswire.com/news-release/2015/04/10/723369/10128367/en/Advaxis-Included-Among-25-Top-Immunotherapy-Companies-in-Newly-Launched-Loncar-Cancer-Immunotherapy-Index-LCINDX.html

CYTR, el RSI está muy cargadito.....
Parece que de momento, quiere parar a descansar en lo sniveles actuales.....
A lo mejor me apeo, y vuelvo a subir más adelante, si relaja un poco....
Un 25% ya me vale, de momento....

NVAX

Jajajaja, triskis, por eso repetí la frase de Pat, pero parece ser que has sido el único que te has dado cuenta del 1 de más.

Vuelvo a XOMA, a ver si mantiene la subida y se dirige a los 5$...

NVAX

Completing Ebola vaccine trials “a challenge” as epidemic wanes

http://www.reuters.com/article/2015/04/10/health-ebola-vaccine-idUSL5N0X72B620150410

Dudas para la posible terminación de los ensayos de las vacunas para el Ébola.